1. 主頁
  2. 胡子祺

胡子祺

WTK_new

羅旭龢基金教授席(公共衞生學)

教授

流行病和生物統計學

  • BS, PhD, FFPH
phone 3917 6709
email joewu@hku.hk
scholarsHub http://hub.hku.hk/cris/rp/rp00517
pub med PubMed
個人簡介

胡教授專門研究疾病的數學和統計建模。他的研究目標包括: (i) 為預防和控制疾病開發實用的分析和策略; (ii) 將研究結果應用於改善衛生的政策。他曾研究過新冠肺炎、季節性/流行性感冒、手足口病、人類乳突病毒、中東呼吸綜合症、黃熱病、子宮頸癌、大腸癌和乳癌。他在麻省理工學院獲得了博士學位（運籌學）和學士學位（化學工程）。

胡教授是醫衞大數據深析實驗室（D24H）的首席科學家。他在 D24H的研究計劃旨在開發用於全球和個人健康保護的人工智能技術和工具，特別關注疫苗猶豫和多重抗體分析。

他主管(i) 香港大學首個慕課流行病。該課自 2014 年首次推出以來，已有超過 40,000 人註冊; (ii) Croucher 暑期課程: Vaccinology for Public Health and Clinical Practice in the 21st Century。

他是 Epidemics 的聯合主編，以及 PLOS Computational Biology 和 PLOS Neglected Tropical Diseases 的副主編。他是世衛WHO Advisory Committee on Immunization and Vaccines-related Implementation Research (IVIR-AC) 的成員。他是麻省理工學院 SOLVE Challenge Leadership Group的成員，也是麻省理工學院HK Innovation Node的SME顧問。他亦是英國公共衛生學院的會員。

發表的部分文章
  1. Wu JT, Leung K, Bushman M, Kishore N, Niehus R, M de Salazar P, Cowling BJ, Lipsitch M, Leung GM. Estimating clinical severity of COVID-19 from the transmission dynamics in Wuhan, China. Nature Medicine. 2020.
  2. Wu JT, Leung K, Leung GM. Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study. Lancet; 395(10225): 689–697. doi:10.1016/S0140-6736(20)30260-9 (2020).
  3. Wang L, Wu JT. Characterizing the dynamics underlying global spread of epidemics. Nature Communications, 9(1):218 (2018).
  4. Leung K, Lipsitch M, Yuen KY, Wu JT. Monitoring the fitness of antiviral-resistant influenza strains during an epidemic: a mathematical modelling study. The Lancet Infectious Diseases, 17(3): 339-347 (2017).
  5. Wu JT, Peak C, Leung GM & Lipsitch M. Fractional Dosing of Yellow Fever Vaccine to Extend Supply: A Modeling Study. The Lancet. doi: 10.1016/S0140-6736(16)31838-4 (2016).
  6. Wu JT, Jit, M, Zheng, Y, Leung, K, Xing, W, Yang, J, Liao, Q, Cowling, BJ, Yang, B, Lau, EH, Takahashi, S, Farrar, JJ, Grenfell, BT, Leung, GM & Yu, H. Routine Pediatric Enterovirus 71 Vaccination in China: a Cost-Effectiveness Analysis. PLoS Medicine 13, e1001975, doi:10.1371/journal.pmed.1001975 (2016).
  7. Wu JT, Ho, A, Ma, ES, Lee, CK, Chu, DK, Ho, PL, Hung, IF, Ho, LM, Lin, CK, Tsang, T, Lo, SV, Lau, YL, Leung, GM, Cowling, BJ & Peiris, JS. Estimating Infection Attack Rates and Severity in Real Time during an Influenza Pandemic: Analysis of Serial Cross-Sectional Serologic Surveillance Data. PLoS Medicine 8, e1001103, doi:10.1371/journal.pmed.1001103 (2011).
  8. Wu JT, Lee, CK, Cowling, BJ & Yuen, KY. Logistical feasibility and potential benefits of a population-wide passive-immunotherapy program during an influenza pandemic. Proceedings of the National Academy of Sciences of the United States of America 107, 3269-3274, doi:10.1073/pnas.0911596107 (2010).
  9. Wu JT, Leung, GM, Lipsitch, M, Cooper, BS & Riley, S. Hedging against antiviral resistance during the next influenza pandemic using small stockpiles of an alternative chemotherapy. PLoS Medicine 6, e1000085, doi:10.1371/journal.pmed.1000085 (2009).
  10. Wu JT, Riley, S, Fraser, C & Leung, GM. Reducing the impact of the next influenza pandemic using household-based public health interventions. PLoS Medicine 3, e361, doi:10.1371/journal.pmed.0030361 (2006).
返回